Argent BioPharma Beheer

Beheer criteriumcontroles 3/4

De CEO Argent BioPharma is Roby Zomer, benoemd in Feb2016, heeft een ambtstermijn van 8.75 jaar. De totale jaarlijkse vergoeding van { bedraagt A$ 417.06K, bestaande uit 92.8% salaris en 7.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 17.12% van de aandelen van het bedrijf, ter waarde € 1.38M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 3.9 jaar.

Belangrijke informatie

Roby Zomer

Algemeen directeur

AU$417.1k

Totale compensatie

Percentage CEO-salaris	92.8%
Dienstverband CEO	8.8yrs
Eigendom CEO	17.1%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Roby Zomer's beloning veranderd ten opzichte van Argent BioPharma's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	AU$417k	AU$387k	-AU$18m
Mar 31 2024	n/a	n/a	-AU$17m
Dec 31 2023	n/a	n/a	-AU$17m
Sep 30 2023	n/a	n/a	-AU$19m
Jun 30 2023	AU$354k	AU$354k	-AU$21m
Mar 31 2023	n/a	n/a	-AU$22m
Dec 31 2022	n/a	n/a	-AU$23m
Sep 30 2022	n/a	n/a	-AU$22m
Jun 30 2022	AU$629k	AU$422k	-AU$20m
Mar 31 2022	n/a	n/a	-AU$19m
Dec 31 2021	n/a	n/a	-AU$18m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	AU$481k	AU$281k	-AU$16m
Dec 31 2020	n/a	n/a	-AU$13m
Sep 30 2020	n/a	n/a	-AU$16m
Jun 30 2020	AU$440k	AU$290k	-AU$19m
Dec 31 2019	n/a	n/a	-AU$18m
Sep 30 2019	n/a	n/a	-AU$14m
Jun 30 2019	AU$495k	AU$330k	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$498k	AU$334k	-AU$8m

Compensatie versus markt: De totale vergoeding ($USD 269.51K ) Roby } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Roby is gestegen terwijl het bedrijf verliesgevend is.

CEO

Roby Zomer (44 yo)

8.8yrs

Tenure

AU$417,064

Compensatie

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Roby Zomer	Co-Founder	8.8yrs	AU$417.06k	17.12% € 1.4m
Igor Bluvstein	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Yifat Steuer	Deputy CEO & COO	2.1yrs	geen gegevens	2.06% € 165.4k
Shachar Shimony	Group General Counsel	no data	geen gegevens	geen gegevens
Masa Oblak	People Manager	no data	geen gegevens	geen gegevens
Amir Polak	Chief Pharmaceutical Development Officer	no data	geen gegevens	1.09% € 87.7k
Sabina Suljakovic	Chief Quality and Commercial Officer	4.2yrs	geen gegevens	geen gegevens
Nadya Lisovoder	Chief Medical Officer	no data	geen gegevens	geen gegevens
Sasha Friedman	Deputy CEO	no data	geen gegevens	geen gegevens
Yair Tal	Chief Information Security Officer	no data	geen gegevens	geen gegevens
Rowan Harland	Company Secretary	1.7yrs	geen gegevens	geen gegevens
Ana Oblak	Group Financial Controller	no data	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van H5O0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Roby Zomer	Co-Founder	8.8yrs	AU$417.06k	17.12% € 1.4m
Ross Grant Walker	Chairman of Strategic Advisory Board	no data	AU$32.00k	geen gegevens
Uri Kramer	Member of Strategic Advisory Board	8.3yrs	geen gegevens	geen gegevens
Layton Mills	Independent Non-Executive Director	1.4yrs	AU$61.92k	geen gegevens
Wendyl D'Souza	Member of Medical Advisory Board	6.3yrs	geen gegevens	geen gegevens
Daniel Robinson	Non-Executive Director	less than a year	AU$41.92k	geen gegevens
Shlomo Sadoun	Member of Advisory Board	less than a year	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van H5O0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Argent BioPharma Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Co-Founder recently bought €1.0m worth of stock

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Less than half of directors are independent

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

Less than half of directors are independent

Recent updates

Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million.

Co-Founder recently bought €1.0m worth of stock

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024

Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange

Less than half of directors are independent

Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023)

Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New major risk - Market cap size

Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer

Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board

New major risk - Market cap size

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million.

MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Board Changes

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million.

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New major risk - Shareholder dilution

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022)

New minor risk - Financial data availability

MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA®

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary

New major risk - Shareholder dilution

MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million.

New major risk - Market cap size

MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director

MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023

First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022)

MGC Pharmaceuticals Limited Announces Change of CFO

Less than half of directors are independent

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2021)

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

First half 2022 earnings: EPS in line with expectations, revenues disappoint

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System